Prevalence of Mycoplasma Conserved DNA in Malignant Ovarian Cancer Detected Using Sensitive PCR–ELISA

doi:10.1006/gyno.1996.0316

Gynecologic Oncology

Volume 63, Issue 2, November 1996, Pages 258-260

https://doi.org/10.1006/gyno.1996.0316 Get rights and content

Abstract

Mycoplasmas are tiny polymorphic prokaryotic organisms (0.2–0.3 μm) that lack a cell wall and reside ubiquitously at the cell membrane or internalized into the cell. The organisms have been implicated in many diseases including functioning as cofactors catalyzing the HIV disease state. The oncogenic potential of mycoplasmas was only recently realized when they were shown to cause chromosomal changes andin vitrocell transformations through gradual progressive chromosomal loss and translocations. While a recent study linked mycoplasmas with gastric cancer, the association between mycoplasmas and ovarian cancer has not been established. Recently, a commercial assay which combined polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) methods was developed for the detection of mycoplasmas. The present objective was to determine the prevalence of mycoplasmas in archived paraffin-embedded malignant ovarian cancer tissue. The combined PCR–ELISA procedure was used with consensus primers targeting for 15 species of mycoplasmas and acholeplasmas. Archived human malignant ovarian cancer tissues (N= 27 cases) embedded in paraffin blocks were processed, and DNA was extracted and the presence of DNA verified. The extracted DNA specimens were randomly divided into three groups for analyses. PCR–ELISA assays were performed on extracted DNA together with appropriate negative and positive controls. The results showed mycoplasmas were present in 59.3% of the malignant ovarian cancer specimens. PCR–ELISA analysis ofNeisseria gonorrheaandChlamydia trachomatiscontrols did not produce cross-reacting false-positive results. The results suggest an association between mycoplasmas and malignant ovarian cancer. A 59.3% prevalence rate was demonstrated for mycoplasmas in paraffin-embedded ovarian cancer tissues. The mechanism involved in oncogenesis by mycoplasmas remains to be elucidated.

References (0)

Cited by (63)

Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma
2023, Cell Reports
The carcinogenesis and progression of hepatocellular carcinoma (HCC) are closely related to viral infection and intestinal bacteria. However, little is known about bacteria within the HCC tumor microenvironment. Here, we showed that intratumoral Mycoplasma hyorhinis (M. hyorhinis) promoted the initiation and progression of HCC by enhancing nuclear ploidy. We quantified M. hyorhinis in clinical tissue specimens of HCC and observed that patients with high M. hyorhinis load had poor prognosis. We found that gastrointestinal M. hyorhinis can retrogradely infect the liver through the oral-duodenal-hepatopancreatic ampulla route. We further found that the increases in mononuclear polyploidy and cancer stemness resulted from mitochondrial fission caused by intracellular M. hyorhinis. Mechanistically, M. hyorhinis infection promoted the decay of mitochondrial fusion protein (MFN) 1 mRNA in an m6A-dependent manner. Our findings indicated that M. hyorhinis infection promoted pathological polyploidization and suggested that Mycoplasma clearance with antibiotics or regulating mitochondrial dynamics might have the potential for HCC therapy.
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis
2022, Seminars in Cancer Biology
Citation Excerpt :
Chlamydia and Mycoplasma infections are among the most common STDs in developed countries and are usually asymptomatic and misidentified [41]. These infectious agents cause salpingitis, psammoma bodies, endometritis, PID, and infertility [18]. Recent studies have shown that the rate of ovarian malignancy is higher in patients with these microorganisms [19,20].
Ovarian cancer is one of the most prevalent cancers with a high mortality rate in women. Published studies indicate that inflammation, DNA damage, and pelvic inflammatory disease (PID) are the most important risk factors for ovarian cancer and this could be induced and exacerbated by infectious agents such as Chlamydia trachomatis and Mycoplasma genitalium. The aim of this study was to determine the association between Chlamydia and Mycoplasma infections and the risk of ovarian cancer.
We carried out a comprehensive search of PubMed, Scopus, Web of Science, Embase, and Google Scholar without limitation on publication date. All relevant studies which investigatived probable potential connection between Chlamydia and Mycoplasma infection and development of ovarian cancer were included.
Eighteen studies comprising a total of 8207 patients were evaluated in the study and this showed that the frequency of infection with Chlamydia and Mycoplasma among ovarian cancer patients was 32.6 % and 23 %, respectively. The results suggested that Chlamydia trachomatis infection increased the overall risk for ovarian cancer by 1.344 fold (OR: 1.344; 95 %CI: 1.19–1.50). Moreover, infection with Mycoplasma infections showed a week but not significant increased risk of ovarian cancer (OR: 1.12; 95 %CI: 0.86–1.44). However, the test for heterogeneity was significant among these studies.
This study confirmed the clinical relevance of Chlamydia and Mycoplasma infection and development of the ovarian cancer risk, although the significance was marginal and study heterogeneity was significant. This highlights the need for further studies in this area.
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential
2022, Seminars in Cancer Biology
Citation Excerpt :
Almost 75 % of the ovarian tumor patients are detected to have diverse microorganisms like Brucella, Chlamydia and Mycoplasma etc. The presence of these microorganisms in the fallopian tubes suggest an association with ovarian carcinogenesis [12,13]. Thus, the association between microbiome dysbiosis and gynecologic cancers is becoming increasing clear, which can mediate physiologic changes and influence the initiation, growth and possibly the outcome of gynecologic cancers [14].
Gynecologic cancers, starting in the reproductive organs of females, include cancer of cervix, endometrium, ovary commonly and vagina and vulva rarely. The changes in the composition of microbiome in gut and vagina affect immune and metabolic signaling of the host cells resulting in chronic inflammation, angiogenesis, cellular proliferation, genome instability, epithelial barrier breach and metabolic dysregulation that may lead to the onset or aggravated progression of gynecologic cancers.
While microbiome in gynecologic cancers is just at horizon, certain significant microbiome signature associations have been found. Cervical cancer is accompanied with high loads of human papillomavirus, Fusobacteria and Sneathia species; endometrial cancer is reported to have presence of Atopobium vaginae and Porphyromonas species and significantly elevated levels of Proteobacteria and Firmicutes phylum bacteria, with Chlamydia trachomatis, Lactobacillus and Mycobacterium reported in ovarian cancer.
Balancing microbiome composition in gynecologic cancers has the potential to be used as a therapeutic target. For example, the Lactobacillus species may play an important role in blocking adhesions of incursive pathogens to vaginal epithelium by lowering the pH, producing bacteriocins and employing competitive exclusions. The optimum or personalized balance of the microbiota can be maintained using pre- and probiotics, and fecal microbiota transplantations loaded with specific bacteria. Current evidence strongly suggest that a healthy microbiome can train and trigger the body's immune response to attack various gynecologic cancers. Furthermore, microbiome modulations can potentially contribute to improvements in immuno-oncology therapies.
Microbial dysbiosis and epigenetics modulation in cancer development – A chemopreventive approach
2022, Seminars in Cancer Biology
Citation Excerpt :
Most of the ovarian cancer tissues have shown Chlamydia, which is not found in controls [165]. Chlamydia has contributed towards cancer by inhibiting apoptosis and increasing vulnerability to infection and in 59 % of cases of ovarian cancer in which Mycoplasma was found [166]. However, many bacteria found in ovarian cancer have been associated with other cancers too [166].
An overwhelming number of research articles have reported a strong relationship of the microbiome with cancer. Microbes have been observed more commonly in the body fluids like urine, stool, mucus of people with cancer compared to the healthy controls. The microbiota is responsible for both progression and suppression activities of various diseases. Thus, to maintain healthy human physiology, host and microbiota relationship should be in a balanced state. Any disturbance in this equilibrium, referred as microbiome dysbiosis becomes a prime cause for the human body to become more prone to immunodeficiency and cancer. It is well established that some of these microbes are the causative agents, whereas others may encourage the formation of tumours, but very little is known about how these microbial communications causing change at gene and epigenome level and trigger as well as encourage the tumour growth. Various studies have reported that microbes in the gut influence DNA methylation, DNA repair and DNA damage. The genes and pathways that are altered by gut microbes are also associated with cancer advancement, predominantly those implicated in cell growth and cell signalling pathways. This study exhaustively reviews the current research advancements in understanding of dysbiosis linked with colon, lung, ovarian, breast cancers and insights into the potential molecular targets of the microbiome promoting carcinogenesis, the epigenetic alterations of various potential targets by altered microbiota, as well as the role of various chemopreventive agents for timely prevention and customized treatment against various types of cancers.
Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential
2022, Seminars in Cancer Biology
The active role of bacteria in oncogenesis has long been a topic of debate. Although, it was speculated to be a transmissible cause of cancer as early as the 16th-century, yet the idea about the direct involvement of bacteria in cancer development has only been explored in recent decades. More recently, several studies have uncovered the mechanisms behind the carcinogenic potential of bacteria which are inflammation, immune evasion, pro-carcinogenic metabolite production, DNA damage and genomic instability. On the other side, the recent development on the understanding of tumor microenvironment and technological advancements has turned this enemy into an ally. Studies using bacteria for cancer treatment and detection have shown noticeable effects. Therapeutic abilities of bioengineered live bacteria such as high specificity, selective cytotoxicity to cancer cells, responsiveness to external signals and control after ingestion have helped to overcome the challenges faced by conventional cancer therapies and highlighted the bacterial based therapy as an ideal approach for cancer treatment. In this review, we have made an effort to compile substantial evidence to support the multidimensional role of bacteria in cancer. We have discussed the multifaceted role of bacteria in cancer by highlighting the wide impact of bacteria on different cancer types, their mechanisms of actions in inducing carcinogenicity, followed by the diagnostic and therapeutic potential of bacteria in cancers. Moreover, we have also highlighted the existing gaps in the knowledge of the association between bacteria and cancer as well as the limitation and advantage of bacteria-based therapies in cancer. A better understanding of these multidimensional roles of bacteria in cancer can open up the new doorways to develop early detection strategies, prevent cancer, and develop therapeutic tactics to cure this devastating disease.
Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs
2015, FEBS Open Bio
Mycoplasmas may colonize tumor tissue in patients. The cytostatic activity of gemcitabine was dramatically decreased in Mycoplasma hyorhinis-infected tumor cell cultures compared with non-infected tumor cell cultures. This mycoplasma-driven drug deamination could be prevented by exogenous administration of the cytidine deaminase (CDA) inhibitor tetrahydrouridine, but also by the natural nucleosides or by a purine nucleoside phosphorylase inhibitor. The M. hyorhinis-encoded CDA_Hyor gene was cloned, expressed as a recombinant protein and purified. CDA_Hyor was found to be more catalytically active than its human equivalent and efficiently deaminates (inactivates) cytosine-based anticancer drugs. CDA_Hyor expression at the tumor site may result in selective drug inactivation and suboptimal therapeutic efficiency.

View all citing articles on Scopus

¹: To whom reprint requests should be addressed. Fax: (909) 478-6450. Http://www.earthlink.net/∼lluivf.

View full text

Regular ArticlePrevalence of Mycoplasma Conserved DNA in Malignant Ovarian Cancer Detected Using Sensitive PCR–ELISA

Abstract

Regular Article
Prevalence of Mycoplasma Conserved DNA in Malignant Ovarian Cancer Detected Using Sensitive PCR–ELISA